BRAIN Biotech AG sharpens focus on profitable growth
Published
12 December 2024
- Combination of BioProducts segment and BioScience Zwingenberg to form the new growth segment BRAINBiocatalysts
- Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15% adjusted EBITDA margin and high R&D ratio
- Completed transactions with Royalty Pharma and Akribion Therapeutics
BRAIN Biotech AG is creating the new growth segment BRAINBiocatalysts in the new financial year 2024/2025, announced at today's Fifth Capital markets Day in Zwingenberg. Bringing together the two previous segments BioProducts and BioScience Zwingenberg ensures an efficient integration of research activities and enables a sharpened focus on the enzyme business to further strengthen the company's liquidity position and profitability.
For the full press release click here
“Our vision is to become a top 10 innovative enzyme player with reliable profitable sales growth and positive cash flows, our strong science foundation will help us reach this vision
